KRENSAVAGE ASSET MANAGEMENT LLC
Q4 2021 Form 13-F
NEW YORK, NEW YORK
CIK 0001609251
· CRD 168976
· SEC-registered investment adviser
$288.3M Reported Value Total
KRENSAVAGE ASSET MANAGEMENT, LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $314,669,759, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
3 funds
· $393.8M gross asset value
Hedge Fund: $393.8M
Source: Form ADV filed 2026-03-25
Reported value
$288.3M
Quarter over quarter
+2.4%
Holdings
10
Top-10 concentration
100.0%
Key People
Form ADV owners & control persons
Michael Paul Krensavage
MANAGING MEMBER/CHIEF EXECUTIVE OFFICER
Paul Joseph Paolino
CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2021 13F record
Q4 2021 13F filing summary
| Period of report | December 31, 2021 |
|---|---|
| Filed | February 15, 2022 |
| Form | 13F-HR |
| Reported value | $288.3M |
| Positions | 10 |
| Change in reported value | -9.6% |
| New positions | 0 |
| Exited positions | 3 |
| Position turnover | 23.1% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
18 | $263.2M |
|
Q1 2026 13F
Filed May 15, 2026
|
20 | $255.7M |
|
Q4 2025 13F
Filed Feb 18, 2026
|
18 | $283.1M |
|
Q3 2025 13F
Filed Nov 17, 2025
|
17 | $234.7M |
|
Q2 2025 13F
Filed Aug 15, 2025
|
15 | $188.9M |
|
Q1 2025 13F
Filed May 15, 2025
|
14 | $180.9M |
|
Q4 2024 13F
Filed Feb 18, 2025
|
12 | $169.0M |
|
Q3 2024 13F
Filed Nov 15, 2024
|
13 | $178.5M |
|
Q2 2024 13F
Filed Aug 15, 2024
|
13 | $217.8M |
|
Q1 2024 13F
Filed May 15, 2024
|
12 | $225.5M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
12 | $281.9M |
|
Q3 2023 13F
Filed Nov 15, 2023
|
12 | $271.6M |
|
Q2 2023 13F
Filed Aug 11, 2023
|
12 | $315.6M |
|
Q1 2023 13F
Filed May 16, 2023
|
12 | $329.3M |
|
Q4 2022 13F
Filed Feb 15, 2023
|
12 | $323.6M |
|
Q3 2022 13F
Filed Nov 15, 2022
|
14 | $314.1M |
|
Q2 2022 13F
Filed Aug 16, 2022
|
14 | $302.5M |
|
Q1 2022 13F
Filed May 17, 2022
|
13 | $290.1M |
|
Q4 2021 13F
Filed Feb 15, 2022
|
10 | $288.3M |
|
Q3 2021 13F
Filed Nov 16, 2021
|
13 | $318.8M |
27 earlier quarters on file — choose one from the quarter menu above.
Top 10 holdings · Q4 2021
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | UTHR UNITED THERAPEUTICS CORP | $44.3M | 15.35% |
| 2 | REGN REGENERON PHARMACEUTICALS | $43.6M | 15.13% |
| 3 | ENTA ENANTA PHARMACEUTICALS INC | $42.2M | 14.63% |
| 4 | MCK MCKESSON CORP | $38.9M | 13.49% |
| 5 | ALKS ALKERMES PLC | $33.6M | 11.64% |
| 6 | EXEL EXELIXIS INC | $28.5M | 9.87% |
| 7 | TARO TARO PHARMACEUTICAL INDUS | $27.0M | 9.37% |
| 8 | BIIB BIOGEN INC | $24.7M | 8.58% |
| 9 | EGRX EAGLE PHARMACEUTICALS INC | $5.4M | 1.88% |
| 10 | NXTC NEXTCURE INC | $186.0K | 0.06% |
Values as reported on the Q4 2021 Form 13F. Every position is in the holdings table below.